Dr. Levy on the Current State of Liquid Biopsies Across Tumor Types

Video

In Partnership With:

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the current state of liquid biopsies across tumor types.

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the current state of liquid biopsies across tumor types.

Initially, liquid biopsies were performed when patients with non—small cell lung cancer (NSCLC) developed resistance to EGFR-targeted therapies. More recently, data sets have shown that liquid biopsies can be used in addition to tissue biopsies in all patients with advanced NSCLC, says Levy.

In gastrointestinal (GI) malignancies and breast cancer, liquid biopsies are being evaluated in the advanced setting as well as in the post-curative intent setting to detect minimal residual disease. However, these tests have shown limited utility, says Levy. The hope is that their application in lung cancer can be extrapolated to breast cancer and GI malignancies, concludes Levy.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD